December 31, 2010

EHSI Secures Rights to Use NASA Developed Stem Cell Technology in China

December 30, 2010 09:12 AM Eastern Time

NASA Developed Bioreactor Could be Huge Boost for Company’s Celulas Genetica Subsidiary

HOUSTON--(BUSINESS WIRE)--Emerging Healthcare Solutions, Inc. (PinkSheets:EHSI) revealed today that their new License Agreement with Regenetech specifically allows the Company to use NASA’s Intrifuge Rotary Cell Culture System in The People’s Republic of China. EHSI has been granted a sub-license for the NASA Intrifuge Rotary Cell Culture System from Regenetech in the License Agreement. What differentiates the NASA technology is the addition of simulated weightlessness in the Rotary Cell Culture System or “bioreactor”. Cell cultures, including stem cells, grown inside the bioreactor look and function much closer to human cells grown within the body than cell cultures grown in Petri dishes. EHSI has also purchased an Intrifuge Rotary Cell Culture System.

This new license is essential to new stem cell research planned by Celulas Genetica, EHSI’s biotech division, including its current endeavor to develop a revolutionary new cure for liver disease known as the Rutherford Procedure. Celulas Genetica is currently planning to test this new procedure in China.

The Rutherford Procedure is a groundbreaking organ regeneration treatment that utilizes proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells. During the procedure, proton therapy will be used to destroy scar-tissue cells in the liver using high-energy proton beams, a non-invasive treatment proven to minimize damage to healthy tissues and to eliminate the side effects (including nausea) of traditional radiation therapy. As the scar tissue is systematically destroyed by the proton therapy, a catheter will deliver the patient’s own cultured stem cells directly to the patient’s liver through the bloodstream. As more and more diseased tissue is destroyed, these cultured stem cells could help regenerate the patient’s damaged, cirrhotic liver into a healthy, functioning organ once more.

Celulas Genetica purchased a license to develop and market the Rutherford Procedure earlier this month, a day before EHSI announced the company’s acquisition. Celulas Genetica is only the latest outpost in Emerging Healthcare Solutions’ global footprint. In addition to its Houston headquarters, the company also maintains business offices in Frankfurt, Germany and Warsaw, Poland.

See more about Celulas Genetica at:

EHSI invests in technology developed to compete in the medical research industry alongside Amyris Inc. (NASDAQ:AMRS), Quest Diagnostics Inc. (NYSE:DGX), Laboratory Corporation of America (NYSE:LH) and Amgen (NASDAQ:AMGN).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.

For more information about EHSI, please visit

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Emerging Healthcare Solutions, Inc.
Cindy Morrissey, 713-821-1486
President and CEO


No comments:

Post a Comment